Lyell Immunopharma (LYEL) Stock Forecast & Price Target

Lyell Immunopharma is supported by a differentiated two-asset CAR T pipeline that targets large, underserved markets in LBCL and mCRC, with ronde-cel’s dual CD19/CD20 design aimed at reducing antigen escape and improving durability while LYL273’s GCC-directed CoupledCAR approach has shown encouraging early efficacy in heavily pretreated mCRC. The company’s outlook is further strengthened by commercially relevant manufacturing control at the LyFE center, which is expected to support more than 1,200 CAR-T doses annually with about 16-day vein-to-site timing and ~97% success rates, reducing a key execution risk for late-stage cell therapy. Financially, the cited analyses point to meaningful long-term value creation from projected peak sales of roughly $1.9B for ronde-cel and $1.6B for LYL273, while the pipeline is further de-risked by FDA Fast Track/RMAT support and a broad patent position.

Lyell Immunopharma is burdened by elevated clinical and regulatory risk because neither LYL314 nor LYL273 has proven a durable, clean safety profile, and the company has already seen grade 3 diarrhea, grade 4 colitis, CRS/ICANS concerns, and even a death from fungal sepsis after LYL273 infusion. The outlook is further pressured by delays, with LYL273 data from the Phase I/II CARABiNER study and the End-of-Phase I FDA meeting now expected in 2027, while the bear case assigns only 15% POS to ronde-cel in DLBCL and 5% to LYL273. On top of that, Lyell faces intense competition, no approved FDA or EMA products, likely future financing needs, and the risk that high CAR-T costs and manufacturing limits could constrain reimbursement and commercialization.